230:
on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include
119:
29:
137:
Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (
559:
141:) and anti-aging drugs. Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.
622:
477:
696:
267:
131:
95:
68:
681:
395:"Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015"
691:
501:
449:
219:
394:
531:
199:
592:
157:, a popular cancer drug as a possible treatment for life extension. He advocates for rapamycin use in longevity research.
686:
676:
567:
671:
630:
243:
Blagosklonny announced that in
January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.
189:
420:
231:
references to
Blagosklonny's own publications in their articles (following the peer review), thereby raising his
123:
63:
701:
593:"LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals"
360:
232:
176:
289:"Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute",
126:, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (
457:
351:
46:
652:
318:"Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute"
376:
130:). Blagosklonny held this position until 2009, when he was appointed professor of oncology at
99:
368:
329:
298:
127:
194:
170:
166:
364:
138:
372:
665:
588:
555:
215:
150:
262:
207:
600:
183:
154:
380:
428:
334:
317:
303:
50:
526:
87:
149:
Blagosklonny has formulated a hypothesis about the possible role of
91:
111:
115:
120:
First Pavlov State
Medical University of St. Petersburg
122:. He was appointed associate professor of medicine at
30:
First Pavlov State
Medical University of St. Peterburg
56:
42:
25:
18:
560:"Oncotarget's Peer Review is Highly Questionable"
118:in experimental medicine and cardiology from the
623:"Mikhail Blagosklonny's Journal Aging: A Review"
349:Stipp, David (2011). "A New Path to Longevity".
8:
15:
333:
302:
187:. In addition, he is associate editor of
550:
548:
268:Roswell Park Comprehensive Cancer Center
132:Roswell Park Comprehensive Cancer Center
96:Roswell Park Comprehensive Cancer Center
69:Roswell Park Comprehensive Cancer Center
251:
218:, a university librarian and expert on
153:in aging and cancer and proposed using
94:. He is an adjunct faculty member at
7:
257:
255:
14:
629:. 6 December 2016. Archived from
373:10.1038/scientificamerican0112-32
697:New York Medical College faculty
532:Cell Death & Differentiation
220:predatory open access publishing
200:Cell Death & Differentiation
1:
114:in internal medicine and his
110:Blagosklonny earned both his
506:Cancer Biology & Therapy
322:Cancer Biology & Therapy
291:Cancer Biology & Therapy
263:"About Mikhail Blagosklonny"
190:Cancer Biology & Therapy
682:Russian medical researchers
86:is a scientist who studies
718:
77:
35:
692:Academic journal editors
328:(9): 753–752. May 2009.
297:(9): 753–752, May 2009,
233:personal citation impact
124:New York Medical College
64:New York Medical College
653:"My battle with cancer"
214:has been criticized by
508:. Taylor & Francis
627:Scholarly Open Access
597:Scholarly Open Access
564:Scholarly Open Access
458:Taylor & Francis
335:10.4161/cbt.8.9.8899
304:10.4161/cbt.8.9.8899
222:, who also included
210:process employed by
193:and a member of the
161:Editorial activities
84:Mikhail Blagosklonny
20:Mikhail Blagosklonny
687:Russian oncologists
633:on 24 December 2016
527:"About the journal"
365:2011SciAm.306f..32S
352:Scientific American
145:Rapamycin and aging
47:Anti-aging medicine
677:Cancer researchers
655:. 26 October 2023.
603:on 2 December 2016
401:. 12 February 2015
672:Biogerontologists
558:(19 April 2016).
502:"Editorial board"
478:"Editorial Board"
450:"Editorial Board"
421:"Editorial Board"
100:Buffalo, New York
81:
80:
37:Scientific career
709:
657:
656:
649:
643:
642:
640:
638:
619:
613:
612:
610:
608:
599:. Archived from
585:
579:
578:
576:
575:
570:on 20 April 2016
566:. Archived from
552:
543:
542:
540:
539:
523:
517:
516:
514:
513:
498:
492:
491:
489:
488:
474:
468:
467:
465:
464:
446:
440:
439:
437:
436:
427:. Archived from
417:
411:
410:
408:
406:
391:
385:
384:
346:
340:
339:
337:
314:
308:
307:
306:
286:
280:
279:
277:
275:
259:
165:Blagosklonny is
128:Albany, New York
16:
717:
716:
712:
711:
710:
708:
707:
706:
662:
661:
660:
651:
650:
646:
636:
634:
621:
620:
616:
606:
604:
587:
586:
582:
573:
571:
554:
553:
546:
537:
535:
525:
524:
520:
511:
509:
500:
499:
495:
486:
484:
476:
475:
471:
462:
460:
448:
447:
443:
434:
432:
419:
418:
414:
404:
402:
393:
392:
388:
348:
347:
343:
316:
315:
311:
288:
287:
283:
273:
271:
261:
260:
253:
249:
241:
195:editorial board
167:editor-in-chief
163:
147:
108:
73:
26:Alma mater
21:
12:
11:
5:
715:
713:
705:
704:
699:
694:
689:
684:
679:
674:
664:
663:
659:
658:
644:
614:
591:(2016-11-20).
589:Beall, Jeffrey
580:
556:Beall, Jeffrey
544:
518:
493:
469:
441:
412:
386:
341:
309:
281:
250:
248:
245:
240:
237:
162:
159:
146:
143:
139:biogerontology
107:
104:
79:
78:
75:
74:
72:
71:
66:
60:
58:
54:
53:
44:
40:
39:
33:
32:
27:
23:
22:
19:
13:
10:
9:
6:
4:
3:
2:
714:
703:
702:Living people
700:
698:
695:
693:
690:
688:
685:
683:
680:
678:
675:
673:
670:
669:
667:
654:
648:
645:
632:
628:
624:
618:
615:
602:
598:
594:
590:
584:
581:
569:
565:
561:
557:
551:
549:
545:
534:
533:
528:
522:
519:
507:
503:
497:
494:
483:
479:
473:
470:
459:
455:
451:
445:
442:
431:on 2009-01-25
430:
426:
422:
416:
413:
400:
399:Bloomberg.com
396:
390:
387:
382:
378:
374:
370:
366:
362:
358:
354:
353:
345:
342:
336:
331:
327:
323:
319:
313:
310:
305:
300:
296:
292:
285:
282:
270:
269:
264:
258:
256:
252:
246:
244:
238:
236:
234:
229:
225:
221:
217:
216:Jeffrey Beall
213:
209:
204:
202:
201:
196:
192:
191:
186:
185:
180:
179:
174:
173:
168:
160:
158:
156:
152:
151:TOR signaling
144:
142:
140:
135:
133:
129:
125:
121:
117:
113:
105:
103:
101:
97:
93:
89:
85:
76:
70:
67:
65:
62:
61:
59:
55:
52:
48:
45:
41:
38:
34:
31:
28:
24:
17:
647:
635:. Retrieved
631:the original
626:
617:
605:. Retrieved
601:the original
596:
583:
572:. Retrieved
568:the original
563:
536:. Retrieved
530:
521:
510:. Retrieved
505:
496:
485:. Retrieved
481:
472:
461:. Retrieved
453:
444:
433:. Retrieved
429:the original
424:
415:
405:November 20,
403:. Retrieved
398:
389:
359:(1): 32–39.
356:
350:
344:
325:
321:
312:
294:
290:
284:
272:. Retrieved
266:
242:
227:
223:
211:
205:
198:
188:
182:
177:
171:
164:
148:
136:
109:
83:
82:
57:Institutions
36:
208:peer review
666:Categories
637:17 January
574:2016-11-20
538:2016-11-20
512:2016-11-20
487:2016-11-20
482:Oncotarget
463:2016-11-20
454:Cell Cycle
435:2016-11-20
247:References
224:Oncotarget
212:Oncotarget
184:Oncotarget
178:Cell Cycle
155:rapamycin
607:19 April
381:22279832
51:oncology
361:Bibcode
274:May 14,
379:
239:Health
181:, and
106:Career
88:cancer
43:Fields
425:Aging
228:Aging
172:Aging
92:aging
639:2017
609:2016
407:2016
377:PMID
276:2021
226:and
206:The
112:M.D.
90:and
369:doi
357:306
330:doi
299:doi
197:of
169:of
116:PhD
98:in
668::
625:.
595:.
562:.
547:^
529:.
504:.
480:.
456:.
452:.
423:.
397:.
375:.
367:.
355:.
324:.
320:.
293:,
265:.
254:^
235:.
203:.
175:,
134:.
102:.
49:,
641:.
611:.
577:.
541:.
515:.
490:.
466:.
438:.
409:.
383:.
371::
363::
338:.
332::
326:8
301::
295:8
278:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.